Drug intelligence / Profile preview

Ad-PD-L1

Development stage: Preclinical
Lead developer: Xuzhou Medical University
Modality: Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies
Administration: Intramuscular

Overview

Ad-PD-L1 is a replication-defective adenovirus vaccine designed to encode the immune checkpoint protein Programmed death-ligand 1 (PD-L1). It functions as an immune checkpoint vaccine, aiming to induce a specific immune response against PD-L1. This mechanism is intended to enhance anti-tumor immunity by activating PD-L1-specific T cells, thereby modulating the tumor microenvironment and overcoming immune evasion in cancers such as renal cell carcinoma. It is currently in preclinical development for renal cell carcinoma.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on Ad-PD-L1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad-PD-L1.

Explore the full profile